Lassen Therapeutics Email Format
Biotechnology ResearchCalifornia, United States11-50 Employees
Lassen Therapeutics is a clinical-stage biotechnology company developing novel antibody therapeutics for fibrotic and inflammatory diseases. It is advancing first-in-class programs that target the interleukin-11 receptor (IL-11R) and interleukin-18 binding protein (IL-18BP), with potential applications in conditions such as thyroid eye disease and idiopathic pulmonary fibrosis. The company aims to deliver therapies that could alter disease progression and improve patient outcomes in serious diseases. Based in San Diego, California, Lassen Therapeutics has pursued collaborations with medical centers, including a 2021 partnership with Cedars-Sinai to advance IPF research. In September 2023 the company disclosed new clinical and preclinical data for LASN01, a candidate for fibro-inflammatory diseases such as TED and IPF.